Cholesterol agonistics

Annals of Internal Medicine

Volumn 124, Issue 5, 1996, Pages 505-508

  LaRosa, John C ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

CLINICAL PRACTICE; CLINICAL PROTOCOL; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SCREENING TEST;

EID: 0030027548     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-5-199603010-00008     Document Type: Review

References (42)

1. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81 1721-33.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group. Lancet 1994;344:1383-9.
3. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 1993;69(1 Suppl):S48-53
4. LaRosa JC. Cholesterol lowering, low cholesterol, and mortality. Am J Cardiol. 1993;72 776-86.
5. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol. 1993;72:1031-7
6. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med. 1996;124:518-31.
7. American College of Physicians. Guideines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:515-7.
8. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993;269 3015-23
9. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1) N Engl J Med 1992;326:242-50.
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2) N Engl J Med. 1992;326 310-8
11. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory responses: a new perspective Hypertension 1995;25 155-61.
12. Ruderman NB, Schneider SH. Diabetes, exercise, and atherosclerosis Diabetes Care. 1992;15 1787-93.
13. St Clair RW. Atherosclerosis regression in animal models: current concepts of cellular and biochemical mechanisms Prog Cardiovasc Dis 1983;26:109-32.
14. Giles WH, Anda RF, Jones DH, Serdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians Progress and missed opportunities. JAMA. 1993;269:1133-8.
15. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA 1984;251:351-74
16. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
17. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH, Li Z, Rasmussen H. et al. Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol. 1995;15 1079-85.
18. Keys A, ed. Coronary heart disease in seven countries Circulation. 1970;41 (Suppl 1):11-1211
19. Kato H, Tillotson J, Nichaman MZ, Rhoads GG, Hamilton HB. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California Am J Epidemiol 1973;97:372-85
20. Robertson TL, Kato H, Rhoads GG, Kagan A, Mormot M, Syme SL, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol. 1977;39:239-43
21. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, et al. Serum cholesterol in young men and subsequent cardiovascular disease N Engl J Med 1993;328:313-8
22. Pedersen TR, Kjekshus J, Pyorala K, Wilhelmsen L, Haghfelt T, Thorgeirson G for the 4S Group. Effect of simvastatin on survival and coronary morbidity in coronary heart disease patients 65 or older [Abstract] Circulation 1995;92(Suppl 1):1672
23. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Athersclerosis Intervention Program. Circulation 1995;92:2419-25
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group N Engl J Med. 1995;333:1301-7.
25. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 1990;264:3007-12
26. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 1995;92:2404-10
27. Elton PJ, Ryman A, Hammer M, Page F. Randomised controlled trial in northern England of the effect of a person knowing their own serum cholesterol concentration J Epidemiol Community Health. 1994;48:22-5
28. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
29. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet 1992;339:563-9.
30. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease Circulation 1992;86 1-11
31. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985;5 141B-149B
32. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit A new look at old data Circulation. 1995;91 2274-82
33. Harris T, Feldman JJ, Kleinman JC, Ettinger WH Jr, Makuc DM, Schatzkin AG. The low cholesterol-mortality association in a national cohort. J Clin Epidemiol. 1992;45:595-601.
34. Iribarren C, Reed DM, Wergowske G, Burchfiel CM, Dwyer JH. Serum cholesterol level and mortality due to suicide and trauma in the Honolulu Heart Program Arch Intern Med. 1995;155 695-700.
35. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults The National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-8.
36. Higgins MW, Luepker, eds. Trends in Coronary Heart Disease Mortality The Influence of Medical Care. New York: Oxford Univ Pr; 1988.vii-x.
37. Pearson TA, Marx HJ. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications [Editorial] Am J Cardiol 1993;72 1072-3
38. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease N Engl J Med. 1980;302:1383-9
39. Austin MA. Small, dense low-density lipoprotein as a risk factor for coronary heart disease Int J Clin Lab Res 1994;24 187-92
40. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited Findings from the Helsinki Heart Study. Arch Intern Med. 1994;154:2714-20
41. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly The Clinical Quality Improvement Network (CQIN) Investigators Am J Cardiol 1995;76 570-3
42. Asch DA, Hershey JC. Why some health policies don't make sense at the bedside Ann Intern Med 1995;122 846-50.